Dyne Therapeutics, Inc. announced promising preclinical data for their therapeutic candidate, DYNE-302, which shows potential for functional improvement in facioscapulohumeral muscular dystrophy ...

Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today announced ...

Dyne Therapeutics, Inc. announced the appointment of Erick J. Lucera as its new Chief Financial Officer, effective March 31, 2025. Lucera brings over 30 years of experience in the life sciences ...

Health and Human Services Secretary Robert F. Kennedy Jr. said on Thursday that the U.S. drugs regulator would look for ways ...

Dyne Therapeutics Inc (NASDAQ:DYN) released initial clinical data from its ACHIEVE trial of DYNE-101 in patients with myotonic dystrophy type 1 (DM1) and its DELIVER trial of DYNE-251 in patients ...

Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on Dyne Therapeutics (DYN – Research Report), boosting the price target to $55.00. Andrew Fein has given his Buy rating due to a ...

Dyne Therapeutics, Inc. experienced a dramatic rise from $6.5 to $46 per share in 2024 followed by a sharp 45% drop to ~$24, now stabilizing at ~$34. The company's IPO in September 2020 raised $ ...

WALTHAM, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with ...

The latest price target for Dyne Therapeutics (NASDAQ:DYN) was reported by HC Wainwright & Co. on May 9, 2025. The analyst firm set a price target for $38.00 expecting DYN to rise to within 12 ...

WALTHAM, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with ...